168 related articles for article (PubMed ID: 24560438)
21. The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal.
Mannelli P; Peindl K; Wu LT; Patkar AA; Gorelick DA
Am J Drug Alcohol Abuse; 2012 May; 38(3):200-5. PubMed ID: 22233189
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
Solli KK; Latif ZE; Opheim A; Krajci P; Sharma-Haase K; Benth JŠ; Tanum L; Kunoe N
Addiction; 2018 Oct; 113(10):1840-1849. PubMed ID: 29806872
[TBL] [Abstract][Full Text] [Related]
23. Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.
Comer SD; Mannelli P; Alam D; Douaihy A; Nangia N; Akerman SC; Zavod A; Silverman BL; Sullivan MA
Am J Addict; 2020 Jul; 29(4):313-322. PubMed ID: 32246728
[TBL] [Abstract][Full Text] [Related]
24. Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.
Shi Z; Wang AL; Jagannathan K; Fairchild VP; O'Brien CP; Childress AR; Langleben DD
J Psychiatry Neurosci; 2018 Jul; 43(4):254-261. PubMed ID: 29947607
[TBL] [Abstract][Full Text] [Related]
25. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.
Springer SA; Di Paola A; Azar MM; Barbour R; Biondi BE; Desabrais M; Lincoln T; Skiest DJ; Altice FL
J Acquir Immune Defic Syndr; 2018 May; 78(1):43-53. PubMed ID: 29373393
[TBL] [Abstract][Full Text] [Related]
26. Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials.
Shulman M; Hu MC; Sullivan MA; Akerman SC; Fratantonio J; Barbieri V; Nunes EV; Bisaga A
Drug Alcohol Depend; 2022 Apr; 233():109343. PubMed ID: 35131528
[TBL] [Abstract][Full Text] [Related]
27. Effects of injectable extended-release naltrexone (XR-NTX) for opioid dependence on residential rehabilitation outcomes and early follow-up.
Leslie DL; Milchak W; Gastfriend DR; Herschman PL; Bixler EO; Velott DL; Meyer RE
Am J Addict; 2015 Apr; 24(3):265-270. PubMed ID: 25655226
[TBL] [Abstract][Full Text] [Related]
28. Problem drinking and low-dose naltrexone-assisted opioid detoxification.
Mannelli P; Peindl K; Patkar AA; Wu LT; Tharwani HM; Gorelick DA
J Stud Alcohol Drugs; 2011 May; 72(3):507-13. PubMed ID: 21513688
[TBL] [Abstract][Full Text] [Related]
29. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.
Friedmann PD; Wilson D; Hoskinson R; Poshkus M; Clarke JG
J Subst Abuse Treat; 2018 Feb; 85():45-48. PubMed ID: 28527855
[TBL] [Abstract][Full Text] [Related]
30. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans.
Bisaga A; Comer SD; Ward AS; Popik P; Kleber HD; Fischman MW
Psychopharmacology (Berl); 2001 Aug; 157(1):1-10. PubMed ID: 11512037
[TBL] [Abstract][Full Text] [Related]
31. Extended-release injectable naltrexone for opioid use disorder: a systematic review.
Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K
Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985
[TBL] [Abstract][Full Text] [Related]
32. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial.
Collins ED; Kleber HD; Whittington RA; Heitler NE
JAMA; 2005 Aug; 294(8):903-13. PubMed ID: 16118380
[TBL] [Abstract][Full Text] [Related]
33. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
Lee JD; Friedmann PD; Kinlock TW; Nunes EV; Boney TY; Hoskinson RA; Wilson D; McDonald R; Rotrosen J; Gourevitch MN; Gordon M; Fishman M; Chen DT; Bonnie RJ; Cornish JW; Murphy SM; O'Brien CP
N Engl J Med; 2016 Mar; 374(13):1232-42. PubMed ID: 27028913
[TBL] [Abstract][Full Text] [Related]
34. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial.
Lee JD; Friedmann PD; Boney TY; Hoskinson RA; McDonald R; Gordon M; Fishman M; Chen DT; Bonnie RJ; Kinlock TW; Nunes EV; Cornish JW; O'Brien CP
Contemp Clin Trials; 2015 Mar; 41():110-7. PubMed ID: 25602580
[TBL] [Abstract][Full Text] [Related]
35. [Injectable extended-release naltrexone for opioid dependence: an open label study of long-term safety and efficacy].
Krupitsky EM; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Blokhina EA; Silverman BL
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):49-56. PubMed ID: 25591636
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Dunn KE; Tompkins DA; Bigelow GE; Strain EC
JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
[TBL] [Abstract][Full Text] [Related]
37. The Effect of Adding Memantine to Clonidine in Reducing Withdrawal Symptoms in Opioid-Dependent Patients: A Double-Blind Randomized Controlled Trial.
Kheirabadi G; Najafian N; Khodadadi F
J Clin Psychopharmacol; 2021 Nov-Dec 01; 41(6):644-649. PubMed ID: 34559090
[TBL] [Abstract][Full Text] [Related]
38. Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?
Sullivan MA; Bisaga A; Mariani JJ; Glass A; Levin FR; Comer SD; Nunes EV
Drug Alcohol Depend; 2013 Nov; 133(1):80-5. PubMed ID: 23827259
[TBL] [Abstract][Full Text] [Related]
39. Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone.
Nunes EV; Gordon M; Friedmann PD; Fishman MJ; Lee JD; Chen DT; Hu MC; Boney TY; Wilson D; O'Brien CP
J Subst Abuse Treat; 2018 Feb; 85():49-55. PubMed ID: 28473233
[TBL] [Abstract][Full Text] [Related]
40. A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts.
Jain K; Jain R; Dhawan A
J Opioid Manag; 2011; 7(1):11-20. PubMed ID: 21434580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
